Targeting ERK5 for Colorectal Cancer Therapy
靶向 ERK5 的结直肠癌治疗
基本信息
- 批准号:10357462
- 负责人:
- 金额:$ 16.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-13 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:BRAF geneCancer CenterCell Differentiation processCell ProliferationCellsClinicClinicalClinical ResearchClinical TrialsColorectal CancerCytokine ReceptorsDataDevelopmentDiagnosisEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEpithelial CellsFamily memberFeedbackGeneticGrowth FactorHumanIn VitroInvestigational TherapiesKRAS oncogenesisKRAS2 geneLeadMAP Kinase GeneMAP2K1 geneMAPK Signaling Pathway PathwayMAPK phosphataseMAPK3 geneMAPK7 geneMEKsMalignant NeoplasmsMalignant neoplasm of lungMediatingMitogen-Activated Protein Kinase InhibitorMolecularMusMutationNeoplasm MetastasisOrganoidsPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhosphoric Monoester HydrolasesPlayPublicationsRas/RafReceptor Protein-Tyrosine KinasesResearch Project GrantsResistanceRoleSamplingSignal PathwaySignal TransductionSpecificityTestingTherapeuticTumor stageUp-Regulationadenomabasecancer cellcolon cancer cell linecolon cancer patientscolorectal cancer metastasiscolorectal cancer treatmenteffective therapygain of function mutationin vivoinhibitor/antagonistintestinal epitheliumintestinal homeostasismelanomamortalitymutantnovelpatient derived xenograft modelpatient responsepre-clinicalpreservationpreventresistance mechanismresponsestem cellstargeted agenttargeted treatmenttherapeutic targettherapy resistanttreatment responsetumortumor growthtumor progression
项目摘要
ABSTRACT
Colorectal cancer (CRC) is diagnosed in about 140,000 patients in the US, with a mortality of 50,000 patients
per year. Almost half of these patients have either a RAS or BRAF mutation for which there is currently no
effective therapy. Activated MAPK signaling plays a major role in the pathogenesis of CRC. Pharmacological
inhibitors of mutant BRAFV600E, MEK1/2, and more recently ERK1/2 have been developed for targeted therapy.
Vertical targeting the MAPK pathway, particularly in combination with epidermal growth factor receptor (EGFR)
inhibitors to prevent its feedback activation holds promise for the systemic treatment of CRC. However, primary
or acquired resistance to targeted therapy is a major obstacle, particularly in CRC as compared with other
cancers such as melanoma and lung cancer. Combinations of EGFR/RAF or RAF/MEK inhibitors have been
tested in the lab and clinic, and recently a triple inhibitor cocktail (EGFR/RAF/MEK) has been clinically evaluated
in BRAFV600E mutant CRC. However, in all the studies reactivation of MAPK signaling was identified as a cause
of resistance and low patient response rates. The mechanism of the reactivation of MAPK signaling is poorly
understood. We have found a novel resistance mechanism in intestinal epithelial cells upon genetic deletion of
ERK1/2 in mice in vivo, as well as in response to treatment of human CRC cells with MEK inhibitors in vitro. This
molecular mechanism involves activation of an atypical MAPK family member, ERK5, which provides a by-pass
signaling pathway to the canonical MAPK signaling pathway. Thus the hypothesis upon which the studies are
based is that “therapeutic targeting of ERK5, particularly when either RAS or BRAF is the cancer driver, in
combination with other targeted agents and/or chemotherapeutics will enhance inhibition of CRC proliferation
and metastasis. Pharmacological targeting of ERK5 in combination with EGFR, RAF and/or MEK inhibitors will
be particularly effective in CRC patients with oncogenic KRAS or BRAF mutations, as this approach prevents
acquired resistance via parallel pathways”. The studies we will conduct are to: investigate the molecular
mechanism causing ERK5 upregulation in CRC cells; evaluate of ERK5 signaling in patient-derived CRC
samples with KRAS mutations; and an investigation of treatment of MEK inhibitor-resistant CRC patient derived
xenografts with ERK5 targeted agents. This an exploratory developmental research project to obtain preclinical
data validating a potential new clinical target, ERK5, responsible for tumor progression, invasion and metastasis
of CRC. The information obtained will provide the basis for a clinical trial of the combination of an ERK5 inhibitor,
with an EGFR/RAF/ MEK inhibitor cocktail in CRC patients.
摘要
在美国约有140,000名患者被诊断为结直肠癌(CRC),其中50,000名患者死亡
每一年。这些患者中几乎有一半患有RAS或BRAF突变,目前还没有
有效的治疗。活化的MAPK信号在CRC的发病机制中起主要作用。药理
突变型BRAFV 600 E、MEK 1/2和最近ERK 1/2的抑制剂已被开发用于靶向治疗。
垂直靶向MAPK通路,特别是与表皮生长因子受体(EGFR)联合使用
抑制剂,以防止其反馈激活持有的CRC的全身治疗的希望。但小学
或获得性耐药的靶向治疗是一个主要障碍,特别是在CRC相比,其他
癌症如黑色素瘤和肺癌。EGFR/RAF或RAF/MEK抑制剂的组合已经被广泛应用。
在实验室和临床测试,最近三重抑制剂鸡尾酒(EGFR/RAF/MEK)已进行临床评估
在BRAFV 600 E突变CRC中。然而,在所有的研究中,MAPK信号的重新激活被确定为一个原因,
抵抗和低病人反应率。MAPK信号通路的再激活机制尚不清楚,
明白我们已经在肠上皮细胞中发现了一种新的耐药机制,
ERK 1/2在小鼠体内以及在体外对用MEK抑制剂处理人CRC细胞的响应。这
分子机制涉及非典型MAPK家族成员ERK 5的激活,其提供旁路
MAPK信号通路的信号通路。因此,研究所依据的假设
基于“ERK 5的治疗靶向,特别是当RAS或BRAF是癌症驱动因素时,
与其它靶向剂和/或化学治疗剂的组合将增强CRC增殖的抑制
和转移。ERK 5与EGFR、RAF和/或MEK抑制剂组合的药理学靶向将
在具有致癌KRAS或BRAF突变的CRC患者中特别有效,因为这种方法可以防止
通过平行途径获得抗性”。我们将进行的研究是:
导致CRC细胞中ERK 5上调的机制;在患者来源的CRC中评价ERK 5信号传导
具有KRAS突变的样本;以及一项针对MEK受体耐药CRC患者的治疗研究,
用ERK 5靶向剂进行异种移植。这是一个探索性的发展研究项目,以获得临床前
数据验证了一个潜在的新的临床靶点,ERK 5,负责肿瘤的进展,侵袭和转移
CRC。所获得的信息将为ERK 5抑制剂,
EGFR/RAF/ MEK抑制剂混合物治疗CRC患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARTH POWIS其他文献
GARTH POWIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARTH POWIS', 18)}}的其他基金
Targeting ERK5 for Colorectal Cancer Therapy
靶向 ERK5 的结直肠癌治疗
- 批准号:
10021322 - 财政年份:2020
- 资助金额:
$ 16.95万 - 项目类别:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
抑制多功能 ALDOA 用于癌症治疗
- 批准号:
10357451 - 财政年份:2018
- 资助金额:
$ 16.95万 - 项目类别:
Inhibiting Multi-Functional ALDOA for Cancer Therapy
抑制多功能 ALDOA 用于癌症治疗
- 批准号:
10494262 - 财政年份:2018
- 资助金额:
$ 16.95万 - 项目类别:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
PLEKHA7 突变 KRAS 治疗的新靶点
- 批准号:
8964895 - 财政年份:2015
- 资助金额:
$ 16.95万 - 项目类别:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
PLEKHA7 突变 KRAS 治疗的新靶点
- 批准号:
9485728 - 财政年份:2015
- 资助金额:
$ 16.95万 - 项目类别:
PLEKHA7 A Novel Target for Mutant KRAS Therapy
PLEKHA7 突变 KRAS 治疗的新靶点
- 批准号:
9301505 - 财政年份:2015
- 资助金额:
$ 16.95万 - 项目类别:
PLEKHA7 and beta-catenin interact to regulate mutant KRas
PLEKHA7 和 β-catenin 相互作用调节突变 KRas
- 批准号:
9251596 - 财政年份:2015
- 资助金额:
$ 16.95万 - 项目类别:
Inhibiting oncogenic KRAS for cancer therapy
抑制致癌 KRAS 用于癌症治疗
- 批准号:
8637741 - 财政年份:2013
- 资助金额:
$ 16.95万 - 项目类别:
相似海外基金
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:
10911713 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
University of Kansas Cancer Center Midwest Pre-Clinical Imaging Center
堪萨斯大学癌症中心中西部临床前影像中心
- 批准号:
10795272 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Georgetown University Lombardi Comprehensive Cancer Center Support Grant
乔治城大学隆巴迪综合癌症中心支持补助金
- 批准号:
10771760 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
- 批准号:
10892335 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
- 批准号:
10709227 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology
堪萨斯大学癌症中心 Paul Calabresi K12 临床肿瘤学职业发展奖
- 批准号:
10647369 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别:
Mayo Comprehensive Cancer Center Grant (MICEO Supp) - Impact of Multi-Channel Communication Campaigns on Cancer Prevention, Control and Survivorship (CaPCaS) in Black, Hispanic, and Rural Populations
梅奥综合癌症中心拨款 (MICEO Supp) - 多渠道沟通活动对黑人、西班牙裔和农村人口癌症预防、控制和生存 (CaPCaS) 的影响
- 批准号:
10889628 - 财政年份:2023
- 资助金额:
$ 16.95万 - 项目类别: